NORGE-MINING-PLC
17.2.2021 08:02:10 CET | Business Wire | Press release
Norge Mining plc , the UK-based exploration company focused on Norway, announces the publication of a maiden Mineral Resource Estimate for the Øygrei area, which confirms the world-class1 characteristics of the Company’s Bjerkreim Exploration Project in south west Norway.
Highlights
- Maiden Mineral Resource Estimate of 1.55 billion tonnes, containing mean grades of 1.74% phosphorus pentoxide, 4.95% titanium dioxide and 0.07% vanadium pentoxide.
- This is a world-class resource of EU Critical Raw Materials, defined as materials of strategic importance for the European economy but for which the EU currently relies on imported supply, and could potentially support a mine life in excess of 50 years.
- Exploration work at Øygrei is ongoing with the aim of improving the understanding of, and extending, the mineral resource.
- During the past two years, Norge Mining has completed more than 25,000m of drilling throughout the Bjerkreim Exploration Project, building on earlier work by the Norway Geological Survey (NGU). The Company expects to report a maiden Mineral Resource Estimate for the Høyland area in the coming months following analysis of information collected from ongoing drilling in that area.
- The Mineral Resource Estimate at Øygrei was prepared according to the JORC2 reporting standard by SRK Exploration Services Ltd (SRK), part of the SRK Group, which is an independent international mining, exploration and environmental consultant.
- The Øygrei Mineral Resource Estimate is summarised below:
Mineral Resource Classification |
Tonnes (millions) |
P2 O5 Grade (%) |
TiO2 Grade (%) |
V2 O5 Grade (%) |
Indicated |
800 |
1.84 |
4.98 |
0.07 |
Inferred |
750 |
1.63 |
4.91 |
0.07 |
Total |
1,550 |
1.74 |
4.95 |
0.07 |
John Vergopoulos, Chief Executive Officer of Norge Mining, said:
“The publication of this Mineral Resource Estimate marks a major milestone for Norge Mining. It confirms that Øygrei alone, which forms a small part of our Bjerkreim Exploration Project, contains a world-class deposit of vanadium, titanium and phosphate. These three minerals are all on the EU’s list of Critical Raw Materials, giving Norway a major opportunity to play a pivotal strategic role in the future supply of these materials.
“Exploration work is ongoing to upgrade and extend the resource at Øygrei, which is just 10 sq km of our total licence area. We are carrying out extensive exploration work in other areas of the Bjerkreim project and expect to announce further Mineral Resource Estimates in the coming months.”
An executive summary of the Øygrei Mineral Resource Estimate is available at the Company’s website: www.norgemining.com
Background to the Bjerkreim Exploration Project
The Bjerkreim Exploration Project is located in the large Bjerkreim-Sokndal Layered Intrusion, which has been widely studied by the Norway Geological Survey (NGU) and other researchers. Norge Mining is focusing on the Bjerkreim Lobe of this intrusion, which forms a large synclinal trough structure. This trough extends at outcrop for some 20km northwest-southeast and up to 10km northeast-southwest. It is known to extend for several kilometres in depth.
The mineralisation consists of primary magmatic mineral assemblages in which vanadium-bearing magnetite, ilmenite (titanium) and apatite (phosphate) represent the minerals of interest. Vanadium, titanium and phosphate are all on the EU’s list of Critical Raw Materials, defined as materials of strategic importance for the European economy but for which the EU currently relies on imported supply.
Through its Norwegian subsidiary Norge Mineraler AS, Norge Mining has 46 exploration licences in south west Norway, totalling more than 400 sq km. During the past two years, the Company has conducted extensive ongoing exploration work at Bjerkreim, including channel sampling, aerial surveys and shallow and deep drilling. In total, more than 25,000m of drilling has been completed.
Øygrei represents one of the areas in the Bjerkreim Exploration Project and is the first area to have reached the stage where a Mineral Resource Estimate can be reported. Øygrei lies on the northern limb of the trough structure where several mineralised zones converge closely.
SRK Exploration Services Ltd (SRK), part of the SRK Group, an international mining, exploration and environmental consultant, has prepared the Mineral Resource Estimate, which brings together the three zones at Øygrei: Zone B, Zone C and New Zone. The diamond drilling programme at Øygrei began in May 2020 and the data cut-off used to produce the resource estimate was 31 December 2020. The data derived from 4,787 assay samples from 24 drill holes.
Øygrei Mineral Resource Estimate
SRK’s initial Mineral Resource Estimate for the Øygrei area of the Bjerkreim Exploration Project, reported according to the JORC Code reporting standard, is summarised below:
Mineral Resource Classification |
Tonnes (millions) |
P2 O5 Grade (%) |
TiO2 Grade (%) |
V2 O5 Grade (%) |
Indicated |
800 |
1.84 |
4.98 |
0.07 |
Inferred |
750 |
1.63 |
4.91 |
0.07 |
Total |
1,550 |
1.74 |
4.95 |
0.07 |
The table shows that the total indicated and inferred mineral resource at Øygrei is 1.55 billion tonnes, which could potentially support a mine life in excess of 50 years.
The vanadium, phosphate and titanium grades are relatively consistent within the three layers that comprise the mineral resource but vary between the layers. Most notably one of the layers, the New Zone, contains a very low phosphate grade (0.11% P2 O5 ) while the other two layers, termed B Zone and C Zone, have mean grades of 1.83% P2 O5 and 2.15% P2 O5 respectively. These two zones together comprise some 1.3 billion tonnes of the total mineral resource and so there would be potential to prioritise the processing of these zones during the mine life and maintain a higher P2 O5 feed grade for a significant period. This will be assessed further as part of the planned Scoping Study.
In reporting a mineral resource, there is a requirement that there are reasonable prospects for eventual economic extraction. In this case, the requirement has been achieved by limiting the tonnage reported to that falling within an open pit which was optimised assuming selling prices of USD230/t of ilmenite, USD97.75/t of phosphate and USD9.2/lb of V2 O5 .
Exploration Target
Norge Mining’s exploration work at Øygrei is ongoing to upgrade and extend the resource. Given the work to extend the resource, SRK has delineated an exploration target, also as defined by the JORC Code, of between 1 and 2 billion tonnes of mineralisation with similar grades to that already reported (between 1.5 and 2% P2 O5 , 4.5 and 5.5% TiO2 and 0.05 and 0.09% V2 O5 ).
This exploration target is based on the assumed continuity of the mineralised layers at Øygrei to the northwest and at depth and has yet to be confirmed by drilling albeit that there is surface geology to support this and the mineralisation drilled to date remains open in these directions. It should be noted that the exploration target potential tonnage and grade estimates are conceptual in nature, that there has been insufficient exploration to estimate a mineral resource and that it is uncertain if further exploration will result in the estimation of a mineral resource.
Next Steps
Exploration work at Øygrei is ongoing with a substantial, planned programme of 14,000m of additional drilling. Data from this drilling work will be used to upgrade and extend the resource and also to provide information for a scoping study, which is expected to begin shortly, to give an initial financial appraisal of the development of Øygrei. The drilling work and scoping study are expected to be completed this year. Norge Mining is also carrying out ongoing exploration work elsewhere in the Bjerkreim Exploration Project.
1 World-class deposit is used in the context of this announcement to mean a deposit of very large size with the potential to provide major economic and strategic benefits.
2 The reporting standard for this statement is the 2012 edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” as published by the Joint Ore Reserves Committee of the Australasian Institute of Mining and Metallurgy, Australian Institute of Geoscientists and Minerals Council of Australia” (the “JORC Code”). The JORC Code is a reporting code which has been aligned with the Committee for Mineral Reserves International Reporting Standards (“CRIRSCO”) reporting template and is an internationally recognised reporting standard that has been adopted worldwide for market-related reporting and financial investments.
The Competent Person who has overall responsibility for the Mineral Resource is Dr Mike Armitage, C.Eng, C. Geol, FGS, MIMM, PhD. Dr Armitage is a Chartered Geologist which is a Recognised Professional Organisation (“RPO”) included in a list promulgated by the Australian Securities Exchange (“ASX”) from time to time. He is a full time employee of SRK Consulting (UK) Ltd and a director of SRK Exploration Services, a corporate consultant and has over 35 years’ experience in the mining and metals industry and also has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the JORC Code. Dr Armitage has been responsible for the reporting of Mineral Resources and Ore Reserves on various properties internationally during the past 30 years.
About Norge Mining plc
Norge Mining plc is a UK-based natural resources company focused on mineral exploration in Norway.
The Company owns 46 exploration licences, totalling more than 400 square kilometres in south-west Norway in an area known to contain vanadium, titanium, phosphate and gold. Norge Mining is currently conducting a programme of exploration work to produce a resource estimate, building on earlier studies by the Norway Geological Survey (NGU).
Norge Mining’s ambition is to become a substantial, sustainable and strategically important exploration and mining business focused on Norway.
The Company was founded in November 2018, is headquartered in the UK and has a 100%-owned Norwegian subsidiary, Norge Mineraler AS.
For further information, please visit www.norgemining.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
